The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.

Michele Maio

Consultant or Advisory Role - MedImmune

Research Funding - MedImmune

Arnaud Scherpereel

Research Funding - MedImmune; SERVIER

Alessandra Di Pietro

Employment or Leadership Position - MedImmune

Paul Vasey

Research Funding - MedImmune

Anne S. Tsao

Consultant or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Genentech; MedImmune; Novartis; Roche

Honoraria - Astellas Pharma; Boehringer Ingelheim; Genentech; MedImmune; Novartis; Roche

Research Funding - Astellas Pharma; Boehringer Ingelheim; Genentech; MedImmune; Novartis; Roche

Luana Calabrò

Research Funding - MedImmune

Dongyue Fu

Employment or Leadership Position - MedImmune

Stock Ownership - AstraZeneca

Paul B. Robbins

Employment or Leadership Position - MedImmune

Stock Ownership - AstraZeneca

Ramy A. Ibrahim

Employment or Leadership Position - AstraZeneca

Stock Ownership - AstraZeneca

Hedy Lee Kindler

Consultant or Advisory Role - MedImmune

Research Funding - MedImmune